Adjuvant Chemotherapy in Gastric Cancer.
- Author:
Min Hee RYU
1
;
Dae Young ZANG
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Review ; Clinical Trial
- Keywords:
Gastric cancer;
Adjuvant;
Chemotherapy
- MeSH:
Chemotherapy, Adjuvant;
Far East;
Humans;
Lymph Node Excision;
Neoplasm Metastasis;
Prognosis;
Recurrence;
Standard of Care;
Stomach Neoplasms
- From:Korean Journal of Medicine
2012;83(3):291-296
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Gastric cancer remains the second most common malignancy worldwide. Surgical resection with D2 lymph node dissection is the standard of care in localized gastric cancer. However about 40% of patients in East Asia and 70% of patients in Western countries experience recurrence after curative surgical resection of localized gastric cancer. Once recurrence occurs, the prognosis of patients is usually dismal, especially in case of distant metastases. Although many clinical trials of adjuvant treatment were conducted to reduce recurrence of gastric cancer after surgical resection, it was controversial until early 2000s whether adjuvant treatment could improve recurrence-free survival or overall survival in gastric cancer. In early 2000s, adjuvant chemoradiation became the standard of care in the US based on the results of SWOG 9008/INT 0116 trial, where only minor portion of patients underwent D2 lymph node dissection. However, adjuvant chemoradiation was considered not applicable to patients with gastric cancer in East Asia where D2 lymph node dissection is the standard surgical method. Recently, large scale phase III studies including ACTS-GC and CLASSIC trial were conducted in the East Asia. Based on those studies, adjuvant chemotherapy is currently accepted as standard treatment in gastric cancer in the East Asia.
